DBV Technologies (NASDAQ: DBVT) and Trinity Biotech PLC (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitabiliy, dividends, valuation, analyst recommendations, risk and earnings.

Institutional and Insider Ownership

48.2% of DBV Technologies shares are held by institutional investors. Comparatively, 66.3% of Trinity Biotech PLC shares are held by institutional investors. 8.2% of Trinity Biotech PLC shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares DBV Technologies and Trinity Biotech PLC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DBV Technologies N/A N/A N/A
Trinity Biotech PLC -98.39% 5.00% 2.63%

Valuation and Earnings

This table compares DBV Technologies and Trinity Biotech PLC’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
DBV Technologies $8.61 million 217.12 -$131.19 million N/A N/A
Trinity Biotech PLC $99.63 million 1.27 $7.90 million ($3.61) -1.59

Trinity Biotech PLC has higher revenue and earnings than DBV Technologies.

Risk and Volatility

DBV Technologies has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Trinity Biotech PLC has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for DBV Technologies and Trinity Biotech PLC, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV Technologies 0 0 8 0 3.00
Trinity Biotech PLC 0 1 0 0 2.00

DBV Technologies presently has a consensus price target of $48.80, suggesting a potential upside of 20.08%. Given DBV Technologies’ stronger consensus rating and higher probable upside, equities analysts clearly believe DBV Technologies is more favorable than Trinity Biotech PLC.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company’s product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Trinity Biotech PLC Company Profile

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.